Emgality® ▼ (galcanezumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Emgality Summary of Product Characteristics (SmPC)

Is Emgality® ▼ (galcanezumab) loading dose repeated following missed doses or treatment interruption?

After missing 3 consecutive monthly doses, repeating a loading dose should be considered from a PK perspective.

Management of Missed or Delayed Doses

Patients should be instructed to inject a missed dose as soon as possible and then resume monthly dosing.1

Do not take a double dose to make up for forgotten injection.2

 If you have forgotten to inject a dose of Emgality, inject the missed dose as soon as possible and then inject the next dose after a month from that date.2

Dose Administration in Phase 3 Migraine Prevention Studies

Galcanezumab has been studied in phase 3 randomized, double-blind, placebo-controlled studies in adult patients for the prevention of

  • episodic migraine (EVOLVE-1 and EVOLVE-2),3,4 and

  • chronic migraine (REGAIN).5

In the phase 3 clinical trials, injections were allowed to be administered within ±2 days of the scheduled visit.6

The recommended dose is 120 mg injected subcutaneously once monthly, with a 240 mg loading dose as the initial dose.6

Considerations for Repeating a Loading Dose After Missed Doses

Clinicians should use their judgment to determine whether a repeat loading dose is needed.

The PK profile of galcanezumab enables some flexibility with regard to when doses are administered. Prolonged dosing delays will decrease galcanezumab concentrations and potentially reduce efficacy.6 It may require some time to re-establish steady-state galcanezumab plasma concentrations when dosing is resumed. Please consider the t1/2 and PK characteristics of galcanezumab to determine whether a repeat loading dose is warranted.

In healthy subjects and patients with episodic or chronic migraine, galcanezumab has a

  • Tmax of 5 days, and

  • t1/2 of 27 days.1,7

Steady state concentrations are achieved by month 1 for the 120-mg monthly dose with a 240-mg loading dose.7 

After missing 3 consecutive monthly doses, approximately 12% of the galcanezumab concentration relative to steady-state will be remaining (Table 1).6 Therefore, after missing 3 consecutive monthly doses, repeating a loading dose should be considered from a PK perspective. Clinicians should use their judgment to determine whether a repeat loading dose is needed.

Table 1. Effect of Missed Monthly Doses on Galcanezumab Steady State Concentrations6

Number of Consecutive
Missed Monthly Doses

Time Since Last Dose
Administration
 (Months)

Concentration Relative to
Steady State (%)
a

1

2

50

2

3

25

3

4

12.5

4

5

6.3

a Assuming 1 month for galcanezumab half-life.

Management of Missed or Incomplete Loading Dose

The galcanezumab steady-state Cmax (Cmax, ss) at monthly doses of 120 mg is achieved after the 240 mg loading dose.1

In the phase 2 dose-ranging study, a loading dose was not implemented.8 In that study, the galcanezumab 120 mg dose did not achieve statistically significant separation from placebo in mean change from baseline migraine headache days until month 3.

Pharmacokinetic modeling of phase 3 data confirmed that the 240 mg loading dose achieved steady-state galcanezumab concentrations by month 1 for the 120 mg/month dose regimen.6

In the event of a missed or incomplete loading dose, complete the loading dose as soon as possible. Then continue with the monthly maintenance dose from the date of last dose.

Therapeutic Indication

Galcanezumab is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.1

References

1. Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Emgality [package leaflet]. Eli Lilly Nederland B.V., The Netherlands.

3. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088. http://dx.doi.org/10.1001/jamaneurol.2018.1212

4. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454. http://dx.doi.org/10.1177/0333102418779543

5. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221. http://dx.doi.org/10.1212/WNL.0000000000006640

6. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

7. Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780

8. Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187-193. http://dx.doi.org/10.1001/jamaneurol.2017.3859

Glossary

PK = pharmacokinetics

t1/2 = elimination half-life

Tmax = time of maximum observed drug concentration

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: June 05, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question